Cellectis Reports 2025 Financials, Advances Cancer Therapy Trials
Biotechnology company Cellectis has released its full-year 2025 financial results and provided updates on its clinical trials for cancer therapies, including promising developments in treatments for relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.
New York – Cellectis, a clinical-stage biotechnology company leveraging gene editing technology, has announced its full-year 2025 financial results and provided an update on its ongoing clinical development programs.
The company's lasme-cel therapy for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) has advanced to its pivotal Phase 2 study. Phase 1 data showed an 83% overall response rate (ORR) at the recommended Phase 2 dose, and in the target Phase 2 population, the ORR reached 100%. All patients in the target group became eligible for transplant. An interim analysis of the Phase 2 trial is expected in Q4 2026, with a Biologics License Application (BLA) submission anticipated in 2028.
Updates were also provided for the eti-cel therapy targeting relapsed or refractory non-Hodgkin lymphoma (r/r NHL). Preliminary Phase 1 data indicated an 88% ORR and a 63% complete response (CR) rate at the current dose level, with 93% of patients having previously received CD19 CAR-T therapy. An additional cohort including low-dose IL-2 is being initiated, and full Phase 1 data are expected by Q4 2026.
Cellectis also reported progress with its partners Servier and AstraZeneca. As of December 31, 2025, the company held $211 million in cash and cash equivalents, providing runway into the second half of 2027. In the field of gene therapy, Cellectis has published research detailing a novel non-viral approach for gene delivery into stem cells.